Nurse Anesthetist - CR in Puxico, MO Accepting Medicare
1 Nurse Anesthetist - CR nurses found. Showing 1 - 1
 James Dwain Holden, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 22888 County Road 283, Puxico, MO 63960 Phone: 573-778-6655 |
News Archive
Gene therapy effectively stabilizes progression of cerebral adrenoleukodystrophy, trial reveals
In a recent clinical trial, a gene therapy to treat cerebral adrenoleukodystrophy (CALD) - a neurodegenerative disease that typically claims young boys' lives within 10 years of diagnosis - effectively stabilized the disease's progression in 88 percent of patients, researchers from the Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Massachusetts General Hospital report today.
Curemark receives FDA clearance for enrollment of children aged 9-12 in CM-AT study for autism
Dr. Joan Fallon, founder and CEO of Curemark, a Rye, New York-based drug research and development company focused on the treatment of Autism and neurological diseases, today announced that the company has received clearance from the Food and Drug Administration (FDA) to commence direct enrollment of children 9-12 years of age into its open-label extension study of CM-AT for children with Autism.
Triple negative breast cancer patients with BRCA gene mutations have low risk of recurrence: Research
Patients with triple negative breast cancer that also have mutations in the BRCA gene appear to have a lower risk of recurrence, compared to those with the same disease without the deleterious genetic mutation, according to researchers at The University of Texas MD Anderson Cancer Center.
sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes
Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, is pleased to note that its partner, sanofi-aventis, has today announced positive top-line results of the Phase III GETGOAL-L-ASIA trial which assessed the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist discovered by Zealand Pharma, in combination with basal insulin.
› Verified 2 days ago